Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Summary

The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response, and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment.

Timeline

Start

2011-06

Primary completion

2014-05

Completion

2015-08

Drugs

Indications